Citizens Reiterates Buy Rating for Exelixis, Inc. (EXEL)
Citizens keeps its buy rating for Exelixis, setting a $55 target, a 3.33% upside from the current price.
Key Points
- Citizens reiterated its buy rating on Exelixis, Inc. (EXEL) with a price target of $55 on June 24, 2026.
- Citizens's $55 price target implies 3.33% upside from Exelixis, Inc.'s ($EXEL) current $53.23 share price.
- Exelixis shares traded at $51.34 on Wednesday, with a market cap of $12.9 billion and a P/E ratio of 17.0.
- Recent insider transactions include planned sales by executives and a series of buys by directors in late May 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Citizens has maintained its buy rating for Exelixis, Inc. (NasdaqGS: EXEL) and set a price target of $55. This reiteration by analyst Silvan Turkcan was announced on June 24, 2026. Shares of Exelixis traded at $51.34 on Wednesday.
Exelixis, Inc. Stock Down 2.2%
Exelixis, Inc. has a market capitalization of approximately $12.9 billion. The company's stock currently trades with a P/E ratio of 17.0 and a forward P/E of 12.7. Its beta, a measure of volatility, stands at 0.435. Over the past 52 weeks, the stock has ranged from a low of $33.76 to a high of $53.93. The 50-day moving average is $48.53, while the 200-day moving average is $43.49. Exelixis also maintains a solid current ratio of 3.26 and a quick ratio of 3.01, with a debt-to-equity ratio of 8.76.
$EXEL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
For its most recent financial period, Exelixis reported revenue of $2.38 billion, reflecting a growth rate of 10%. The company achieved a net margin of 35.1% and a return on equity (ROE) of 41.0%. Earnings per share (EPS) were $3.02. The next earnings report is scheduled for August 4, 2026.
Insider Buying and Selling at Exelixis, Inc.
Recent insider activity at Exelixis includes several transactions. On June 1, 2026, Sue Gail Eckhardt sold 9,812 shares at an average price of $50.14, and Jack Wyszomierski sold 3,925 shares at $50.55, both as planned sales. In contrast, on May 27, 2026, multiple directors, including Bob Oliver, Stelios Papadopoulos, Jack Wyszomierski, and Tomas Heyman, each acquired 8,367 shares in non-planned purchases.
Analysts Set New Price Targets
On June 24, 2026, Citizens maintained its buy rating on Exelixis with a $55 price target. Other firms have also weighed in recently. On May 7, 2026, HC Wainwright & Co. maintained a buy rating with a $56 target. TD Cowen also kept a buy rating with a $55 target on May 6, 2026. Meanwhile, firms like Morgan Stanley, Stifel, and Wells Fargo have maintained hold ratings with targets ranging from $40 to $50. The consensus among 16 analysts is a buy recommendation, with an average target price of $49.
About Exelixis, Inc.
Exelixis, Inc. is a biotechnology company based in Alameda, California, focused on developing treatments for cancer. The company is known for its CABOMETYX and COMETRIQ products, which are used to treat various types of cancer. Led by CEO Dr. Michael M. Morrissey, the company employs 1,077 people and engages in research collaborations with several major pharmaceutical firms.
Bottom Line
Citizens' reiteration of a buy rating for Exelixis, Inc. with a $55 price target reflects confidence in the company's potential. Investors and analysts alike are watching Exelixis closely, given its robust financial performance and strategic partnerships in cancer treatment. While the latest analyst ratings provide insight, it's important to remember that these are backward-looking statements and may not reflect future performance.
Get Exelixis, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EXEL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.